SCHEMBL201285

SCHEMBL201285

CCCc1ccc(-c2ccc(C(=O)NC(CCSC)C(=O)O)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.60
CA1 P00915 3/20 0.60
CA12 O43570 2/20 0.59
CA9 Q16790 2/20 0.59
L3MBTL1 Q9Y468 1/20 0.58
ALDH1A1 P00352 2/20 0.56
NPSR1 Q6W5P4 1/20 0.56
USP2 O75604 1/20 0.53
TP53 P04637 1/20 0.53
ALOX15 P16050 1/20 0.53
MAPK1 P28482 1/20 0.53
TAS1R3 Q7RTX0 1/20 0.50
TAS1R1 Q7RTX1 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
CTSB P07858 1/20 0.48
FOLH1 Q04609 1/20 0.48
FNTA P49354 2/20 0.48
FNTB P49356 2/20 0.48
PLK1 P53350 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL202188 0.89 TAS1R3 (0.53) CA2CA1CA12CA9L3MBTL1
SCHEMBL203577 0.88 L3MBTL1 (0.56) CA2CA1CA12CA9L3MBTL1
SCHEMBL201891 0.88 L3MBTL1 (0.76) CA2CA1CA12CA9L3MBTL1
SCHEMBL201908 0.88 L3MBTL1 (0.76) CA2CA1CA12CA9L3MBTL1
SCHEMBL203576 0.88 L3MBTL1 (0.56) CA2CA1CA12CA9L3MBTL1
SCHEMBL23273784 0.86 L3MBTL1 (0.76) CA2CA1CA12CA9L3MBTL1
SCHEMBL201383 0.83 CA2 (0.52) CA2CA1CA12CA9L3MBTL1
SCHEMBL6624791 0.82 CA2 (0.65) CA2CA1CA12CA9L3MBTL1
SCHEMBL6624794 0.82 CA2 (0.65) CA2CA1CA12CA9L3MBTL1
SCHEMBL9830233 0.80 CA2 (0.70) CA2CA1CA12CA9L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 CA2 2397/4885CA1 4292/4885CA12 4260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.